Weekly Research Analysts’ Ratings Changes for Adaptive Biotechnologies (ADPT)

A number of firms have modified their ratings and price targets on shares of Adaptive Biotechnologies (NASDAQ: ADPT) recently:

• 5/12/2026 – Adaptive Biotechnologies had its price target lowered by Morgan Stanley from $21.00 to $18.00. They now have an “equal weight” rating on the stock.
• 5/6/2026 – Adaptive Biotechnologies had its price target raised by TD Cowen from $19.00 to $21.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Adaptive Biotechnologies had its price target lowered by JPMorgan Chase & Co. from $21.00 to $19.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Adaptive Biotechnologies had its “buy” rating reaffirmed by Guggenheim. They now have a $21.00 price target on the stock.
• 5/6/2026 – Adaptive Biotechnologies had its “buy” rating reaffirmed by BTIG Research. They now have a $22.00 price target on the stock.
• 4/20/2026 – Adaptive Biotechnologies had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Adaptive Biotechnologies

In other news, CEO Chad M. Robins sold 470,167 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $6,192,099.39. Following the completion of the sale, the chief executive officer owned 2,301,113 shares in the company, valued at approximately $30,305,658.21. This trade represents a 16.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Harlan S. Robins sold 470,266 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $6,193,403.22. Following the transaction, the insider directly owned 1,522,058 shares of the company’s stock, valued at approximately $20,045,503.86. This represents a 23.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 2,417,168 shares of company stock valued at $34,153,000. Insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.